Bimolane (also known as AT-1727) is a novel, potent topoisomerase II inhibitor that has been widely used for the treatment of cancer, psoriasis, and uveitis in humans.

Ellipticine HCl, originally identified as a natural product, is a DNA-damaging agent acting as a prodrug whose pharmacological efficiencies and genotoxic side effects are dictated by activation with cytochrome P450 (CYP).

Bisantrene HCl (CL216942 and NSC337766), the hydrochloride salt of Bisantrene, is potent inhibitor of topoisomerase II and DNA intercalators with anticancer activity.

SW044248 is a novel, potent and selective Topoisomerase I inhibitor that was identified through a screen for chemicals selectively toxic for non-small cell lung cancer (NSCLC) cell lines.

Genz-644282, formerly known as SAR402674, is a novel, potent and non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity.

LMP744 (Mj-III-65, NSC-706744) is a novel and potent DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity.

Epirubicin (IMI 28; IMI-28; 4′-epidoxorubicin; epiADR; epidoxorubicin; Ellence; Pharmorubicin PFS) is an anthracycline-based anticancer agent used for chemotherapy.

(±)-10-Hydroxycamptothecin, a naturally occuring indole alkaloid isolated from Camptotheca acuminate, is a cell-permeable and potent inhibitor of topoisomerase I.

Ellipticine, originally identified as a natural product, is a DNA-damaging agent acting as a prodrug whose pharmacological efficiencies and genotoxic side effects are dictated by activation with cytochrome P450 (CYP).

Aldoxorubicin (MC-DOXHZN; INNO206, Doxo-EMCH, INNO-206) is an albumin-binding prodrug of doxorubicin, which is a DNA topoisomerase II inhibitor and anthracycline antibiotic anticancer drug.